Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.1450 (2.69%) ($5.1450 - $5.1450) on Fri. May. 7, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.07% (three month average) | RSI | 50 | Latest Price | $5.1450(2.69%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.7% a day on average for past five trading days. | Weekly Trend | ADMS advances 0.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) EWG(32%) EWI(30%) XLE(25%) EWP(21%) UNG(20%) | Factors Impacting ADMS price | ADMS will decline at least -2.035% in a week (0% probabilities). TAN(-12%) FXI(-25%) LQD(-18%) MCHI(-17%) KWEB(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.035% (StdDev 4.07%) | Hourly BBV | -0.7 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.33 | 5 Day Moving Average | $5.38(-4.37%) | 10 Day Moving Average | $5.55(-7.3%) | 20 Day Moving Average | $5.33(-3.47%) | To recent high | -19.2% | To recent low | 2.7% | Market Cap | $146m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |